Telix Pharmaceuticals Limited (ASX:TLX)

Market Cap	5.03B
Revenue (ttm)	1.01B
Net Income (ttm)	16.54M
Shares Out	338.40M
EPS (ttm)	0.07
PE Ratio	228.33
Forward PE	137.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,677,893
Average Volume	3,412,776
Open	15.26
Previous Close	15.38
Day's Range	14.78 - 15.26
52-Week Range	13.30 - 31.97
Beta	2.27
RSI	45.15
Earnings Date	Oct 16, 2025

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 234
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: TLX

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was $484.69 million, an increase of 41.49% compared to the previous year's $342.57 million. Earnings were $30.89 million, an increase of 769.68%.

Financial numbers in USD